A phase Ib/II study of cancer sternness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts).

被引：14
|
作者：
Bekaii-Saab, Tanios S.
Starodub, Alexander
El-Rayes, Bassel F.
O'Neil, Bert H.
Shanda, Safi
Ciombor, Kristen Keon
Noonan, Anne M.
Hanna, Wahid Tewfik
Sehdev, Amikar
Shaib, Walid Labib
Mikhail, Sameh
Neki, Anterpreet S.
Oh, Cindy
Li, Youzhi
Li, Wei
Borodyansky, Laura
Li, Chiang
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.4106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4106
引用
收藏
页数：5
相关论文
共 50 条
  • [1] A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts)
    Bekaii-Saab, T.
    Starodub, A.
    El-Rayes, B.
    O'Neil, B.
    Shahda, S.
    Ciombor, K.
    Noonan, A.
    Hanna, W.
    Sehdev, A.
    Shaib, W.
    Mikhail, S.
    Neki, A.
    Oh, C.
    Li, Y. Z.
    Li, W.
    Borodyansky, L.
    Li, C. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] A phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Shahda, Safi
    El-Rayes, Bassel F.
    O'Neil, Bert H.
    Starodub, Alexander
    Hanna, Wahid Tewfik
    Borodyansky, Laura
    Oh, Cindy
    Li, Chiang
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [3] CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC).
    Bekaii-Saab, Tanios S.
    Li, Chung-Pin
    Okusaka, Takuji
    O'Neil, Bert H.
    Reni, Michele
    Tabernero, Josep
    Qin, Shukui
    Van Cutsem, Eric
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] A phase Ib extension study of cancer sternness inhibitor BB608 (napabucasin) in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic cancer.
    El-Rayes, Bassel F.
    Shanda, Safi
    Starodub, Alexander
    O'Neil, Bert H.
    Hanna, Wahid Tewfik
    Shaib, Walid Labib
    Oh, Cindy
    Li, Wei
    Li, Youzhi
    Borodyansky, Laura
    Li, Chiang
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Phase 1b/II study of cancer sternness inhibitor napabucasin (BBI-608) in combination with FOLFIRI plus /- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).
    Bendel, Johanna C.
    Hubbard, Joleen Marie
    O'Neil, Bert H.
    Jonker, Derek J.
    Starodub, Alexander
    Peyton, James D.
    Pitot, Henry C.
    Halfdanarson, Thorvardur Ragnar
    Nadeau, Benjamin Rolland
    Zubkus, John D.
    Adesunloye, Bamidele
    Edenfield, William Jeffery
    Li, Youzhi
    Li, Wei
    Grothey, Axel
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Weiss, Glen J.
    Blaydorn, Lisa
    Beck, Julia
    Bornemann-Kolatzki, Kirsten
    Urnovitz, Howard
    Schutz, Ekkhard
    Khemka, Vivek
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (01) : 96 - 102
  • [7] Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Glen J. Weiss
    Lisa Blaydorn
    Julia Beck
    Kirsten Bornemann-Kolatzki
    Howard Urnovitz
    Ekkhard Schütz
    Vivek Khemka
    Investigational New Drugs, 2018, 36 : 96 - 102
  • [8] Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) plus nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).
    Bekaii-Saab, Tanios S.
    Starodub, Alexander
    El-Rayes, Bassel F.
    Shahda, Safi
    O'Neil, Bert H.
    Noonan, Anne M.
    Shaib, Walid Labib
    Hanna, Wahid Tewfik
    Mikhail, Sameh
    Neki, Anterpreet S.
    Chang, Yue
    Dai, Xiaoshu
    Li, Wei
    Brooks, Emily
    Oh, Cindy
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Napabucasin plus nab-paclitaxel with gemcitabine in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC): Results from the phase III CanStem111P study
    Bekaii-Saab, T.
    Okusaka, T.
    Goldstein, D.
    Oh, D-Y.
    Ueno, M.
    Ioka, T.
    Fang, W.
    Anderson, E. C.
    Noel, M. S.
    Reni, M.
    Choi, H. J.
    Goldberg, J.
    Oh, S. C.
    Li, C-P.
    Tabernero, J.
    Li, J.
    Foos, E.
    Oh, C.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S1084 - S1085
  • [10] CanStem111P trial: A phase III study of napabucasin plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC)
    Bekaii-Saab, T.
    Goldstein, D.
    Li, C. P.
    Okusaka, T.
    O'Neil, B.
    Reni, M.
    Tabernero, J.
    Qin, S.
    Van Cutsem, E.
    Borodyansky, L.
    Li, C. J.
    ANNALS OF ONCOLOGY, 2017, 28
12345